Edition:
United Kingdom

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

93.08EUR
22 Oct 2018
Change (% chg)

-- (--)
Prev Close
€93.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
505,718
52-wk High
€94.62
52-wk Low
€74.54

Latest Key Developments (Source: Significant Developments)

Merck: FDA Accepts File For Cladribine Tablets As Potential Treatment For Relapsing Forms Of Multiple Sclerosis
Monday, 30 Jul 2018 

July 30 (Reuters) - MERCK KGAA ::FDA ACCEPTS FILE FOR CLADRIBINE TABLETS AS POTENTIAL TREATMENT FOR RELAPSING FORMS OF MULTIPLE SCLEROSIS.NEW DRUG APPLICATION INCLUDES CLOSE TO 12,000 PATIENT YEARS OF DATA AND UP TO 10 YEARS OF SAFETY DATA IN SOME PATIENTS.  Full Article

FDA Accepts File For Cladribine Tablets As Potential Treatment For Relapsing Forms Of Multiple Sclerosis
Monday, 30 Jul 2018 

July 30 (Reuters) - Merck KGaA ::FDA ACCEPTS FILE FOR CLADRIBINE TABLETS AS POTENTIAL TREATMENT FOR RELAPSING FORMS OF MULTIPLE SCLEROSIS.EMD SERONO - RESUBMISSION OF NEW DRUG APPLICATION FOR CLADRIBINE TABLETS.EMD SERONO - RESUBMISSION FOR CLADRIBINE TABLETS AS POTENTIAL TREATMENT FOR RELAPSING FORMS OF MS ACCEPTED FOR FILING BY FDA.  Full Article

RBK EMD raises 7 bln won in private placement
Friday, 27 Jul 2018 

July 27 (Reuters) - RBK EMD Co Ltd <106080.KQ> ::Says it raised 7 billion won in private placement of 12,367,491 shares of the company.  Full Article

Merck KGaA Performance Materials CEO Says Doesn't Rule Out Smaller M&A
Tuesday, 3 Jul 2018 

July 3 (Reuters) - Merck KGaA Performance Materials division CEO::SAYS BIG ACQUISITIONS WON'T HAPPEN UNTIL AFTER 2019, BUT CANNOT RULE OUT SMALLER ONES BEFORE THEN.SAYS DOESN'T SEE NEGATIVE IMPACT FROM U.S.-CHINA TRADE TARIFFS, MERCK DOESN'T HAVE MATERIAL STREAMS ACROSS AFFECTED REGIONS.  Full Article

Merck KGaA Receives Patent For CRISPR Technology In China
Monday, 23 Apr 2018 

April 23 (Reuters) - Merck KGaA ::MERCK RECEIVES PATENT FOR CRISPR TECHNOLOGY IN CHINA.  Full Article

P&G Acquires the Consumer Health Business Of Merck KGaA, Darmstadt, Germany
Thursday, 19 Apr 2018 

April 19 (Reuters) - Procter & Gamble Co ::ACQUIRES THE CONSUMER HEALTH BUSINESS OF MERCK KGAA, DARMSTADT, GERMANY.SAYS ANNOUNCED IT HAS SIGNED AN AGREEMENT TO ACQUIRE CONSUMER HEALTH BUSINESS OF MERCK KGAA, DARMSTADT, GERMANY.HAS SIGNED AGREEMENT TO ACQUIRE CONSUMER HEALTH BUSINESS OF MERCK KGAA, FOR PURCHASE PRICE OF ABOUT 3.4 BILLION EURO.  Full Article

P&G Nears Deal To Acquire Merck KGaA's Consumer-Health Unit - WSJ
Thursday, 19 Apr 2018 

April 18 (Reuters) - :P&G NEARS DEAL TO ACQUIRE MERCK KGAA’S CONSUMER-HEALTH UNIT - WSJ, CITING SOURCES.  Full Article

Forty Seven Says Agreement With Merck KGAA To Conduct Clinical Trials For Patients With Ovarian Cancer
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Merck KGAA ::FORTY SEVEN - AGREEMENT WITH MERCK KGAA TO CONDUCT PHASE 1B CLINICAL TRIAL COMBINING HU5F9-G4 WITH AVELUMAB IN PATIENTS WITH OVARIAN CANCER.  Full Article

Juniper Pharmaceuticals Announces ‍Extension Of Supply Agreement For Crinone
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS ANNOUNCES 4.5-YEAR EXTENSION THROUGH 2024 OF CRINONE® SUPPLY AGREEMENT WITH MERCK KGAA, DARMSTADT, GERMANY.JUNIPER PHARMACEUTICALS INC - ‍EXTENSION OF SUPPLY AGREEMENT FOR CRINONE WITH AFFILIATE OF MERCK KGAA.JUNIPER PHARMACEUTICALS INC - ‍AMENDED AGREEMENT EXTENDS SUPPLY TERM AN ADDITIONAL 4.5 YEARS AND AT LEAST THROUGH TO DECEMBER 31, 2024​.  Full Article

Juniper Pharmaceuticals Outlines Strategic Priorities For 2018 And Reports Recent Portfolio Progress
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Juniper Pharmaceuticals Inc ::JUNIPER PHARMACEUTICALS OUTLINES STRATEGIC PRIORITIES FOR 2018 AND REPORTS RECENT PORTFOLIO PROGRESS.JUNIPER PHARMACEUTICALS INC - ON TRACK TO BE CASH FLOW POSITIVE IN 2018.JUNIPER PHARMACEUTICALS INC - CONTINUED "STRONG" DOUBLE-DIGIT REVENUE GROWTH FOR CRINONE AND JPS EXPECTED IN 2018.JUNIPER - ACTIVE DISCUSSIONS WITH MERCK KGAA TO EXTEND CRINONE PROGESTERONE GEL AGREEMENT ARE PROGRESSING.JUNIPER PHARMACEUTICALS INC - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0101, THE OXYBUTYNIN IVR FOR TREATMENT OF OVERACTIVE BLADDER.JUNIPER PHARMACEUTICALS - PARTNERING OPPORTUNITIES ARE BEING "EXPLORED" FOR JNP-0301, A NATURAL PROGESTERONE IVR FOR PREVENTION OF PRE-TERM BIRTH.  Full Article

German stocks - Factors to watch on Oct. 22

FRANKFURT/BERLIN, Oct 22 - The following are some of the factors that may move German stocks on Monday: